Superworth

Alphatec ATEC

Medical - Instruments & Supplies, Healthcare
$7.31
+3.84%
Market cap
$1.1B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
1.4×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$839.7M
+15% on a year ago
Net margin
−10.3%
Free cash flow yield
0.3%

Alphatec trades at 1.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $839.7M over the last twelve months, up 15% on a year earlier with a −10% net margin.

Charts

Financials

Income statement for ATEC, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$138M+30%$138.5M+27%$145.6M+25%$150.7M+27%$176.8M+28%$169.2M+22%$185.5M+28%$196.5M+30%$212.9M+20%$192.1M+14%$213.5M+15%$221.2M+13%
Cost of revenue$42.8M+15%$41.1M+6%$43M−18%$48M+26%$55.2M+29%$53.2M+29%$56.4M+31%$59.2M+23%$63.4M+15%$55.6M+5%$59.4M+5%$62.9M+6%
Gross profit$95.2M+38%$97.4M+38%$102.6M+59%$102.7M+28%$121.6M+28%$116M+19%$129.1M+26%$137.3M+34%$149.5M+23%$136.5M+18%$154.1M+19%$158.2M+15%
R&D$22.3M+92%$18M+36%$19.1M+31%$20.4M+2%$23.2M+4%$16.6M−8%$18.3M−4%$18.7M−8%$22.3M−4%$17.6M+6%$18.2M−1%$18M−4%
SG&A$104.1M+27%$113.6M+25%$112.7M+29%$109.2M+20%$114.7M+10%$127M+12%$118.5M+5%$124.3M+14%$128.7M+12%$137.1M+8%$134M+13%$132.5M+7%
−$44.8M+28%−$43.3M+7%−$35.3M−29%−$33.7M−12%−$23.8M−47%−$44.3M+2%−$13.1M−63%−$15.9M−53%−$8.8M−63%−$22.6M−49%−$1.9M−85%$3.2M
Interest expense$4.4M+232%$5.3M+38%$5.8M+49%$6.6M+47%$7.2M+62%$7.8M+47%$12.3M+112%$12.9M+96%$12.9M+80%$11.7M+50%$11M−11%$10.6M−18%
Pre-tax income−$49.2M+39%−$48.6M+12%−$41M−20%−$39.7M−7%−$32.9M−33%−$52M+7%−$41.2M+1%−$28.5M−28%−$21.7M−34%−$33.9M−35%−$25.6M−38%−$7.5M−74%
−$124K−76%−$69K−$286K+472%−$36K−69%$441K−$64K−7%−$37K−87%$74K−$18K$50K$156K$2M+2595%
Net income−$49.1M+41%−$48.5M+11%−$40.7M−21%−$39.6M−7%−$33.3M−32%−$51.9M+7%−$41.1M+1%−$28.6M−28%−$21.7M−35%−$33.9M−35%−$25.8M−37%−$5.5M−81%
−$0.37+12%−$0.34−15%−$0.29−33%−$0.28−20%−$0.23−38%−$0.35+3%−$0.27−7%−$0.19−32%−$0.14−39%−$0.22−37%−$0.16−41%−$0.03−84%
133.8M+26%141M+29%142.7M+20%143.5M+17%144.6M+8%146.7M+4%149.9M+5%151.4M+6%152.1M+5%154.1M+5%156.6M+4%157.4M+4%

EPS, diluted: 17 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 8 periods, Q2 FY10 to Q1 FY12: not printed by the filing, worked out from its own lines. 13 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Alphatec's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ATECAlphatec$1.1Bn/mn/a1.4×+15%−10.3%
BVSBioventus$1.1B17.1×27.1×1.9×+4%9.4%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
STAAStaar Surgical$1.3B356×144×3.7×+51%1.1%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
CDRECadre$1.3B38.9×35.9×2.0×+20%5.3%
EYENational Vision$1.4B28.1×52.7×0.7×+8%2.5%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
LMATLemaitre Vascular$1.9B28.5×42.0×7.1×+12%25.0%
INSPInspire Medical Systems$1.9B14.5×56.6×2.2×−0%15.0%
UFPTUFP Technologies$2.2B30.6×25.6×3.5×+7%11.4%
Peer median$1.3B29.6×41.7×2.1×+8%7.7%

More on Alphatec

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .